New Haven, CT – According to filings with the U.S. Securities and Exchange Commission, Simcha Therapeutics is raising $39,999,995.00 in new funding. Sources indicate as part of senior management President, Aaron Ring played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Simcha Therapeutics
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. Simchas lead program, ST-067, is a designer IL-18 cytokine that has shown potent antitumor effects in animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors, as described in Nature in June 2020. A Phase 1 trial is expected to be launched in the first half of 2021. Simcha was founded by Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine. The company has received $25 million in funding to date and is based in New Haven, Conn.

To learn more about Simcha Therapeutics, visit http://www.simchatx.com/

Contact:
Aaron Ring, President
509-939-4681
https://www.linkedin.com/in/aaron-ring-b34b4869/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved